#437: 16 C.F.R. Part 801: Premerger Notification: Reporting and Waiting Period: NPRM: Proposed Amendments to Rules For the Reportability of A Transaction Involving the Transfer of Rights to A Patent in the Pharmaceutical Industry; Project No. P989316

Matter Number:

P989316

Related Federal Register Notice:
16 CFR Part 801: Premerger Notification; Reporting and Waiting Period Requirements; Notice of Proposed Rulemaking (August 20, 2012)

Comments

Comments From Members of Congress

Summaries of Communications

  1. application/pdf icon Summary of Communications Placed on the Public Record Pursuant to Commission Rule 1.26(b)(5), 16 C.F.R. 1.26(b)(5) (2013) (April 3, 2013 Meeting Attended by Commissioner Wright, Three of His Attorney Advisors, Three Commission Staff Members, and Representatives of the Pharmaceutical Research and Manufacturers of America) (10.62 KB)
  2. application/pdf icon Summary of Communications Placed on the Public Record Pursuant to Commission Rule 1.26(b)(5), 16 C.F.R. 1.26(b)(5)(2013) (April 18, 2013 Meeting Attended by Chairwoman Ramirez, One of Her Attorney Advisors and Her Honors Paralegal, and Representatives of the Pharmaceutical Research and Manufacturrers of America) (23.38 KB)
  3. application/pdf icon Letter Dated June 7, 2013, From Stephen Weissman, Baker Botts LLP, Representing the Pharmaceutical Research and Manufacturers of America, to Commissioner Wright, Placed on the Public Record Pursuant to Commission Rule 1.26(b)(5), 16 C.F.R. 1.26(b)(5)(2013). (1.11 MB)
  4. application/pdf icon Summary of Communications Placed on the Public Record Pursuant to Commission Rule 1.26(b)(5), 16 C.F.R. 1.26(b)(5) (2013) (March 13, 2013 Meeting Attended by Commissioner Brill, Two of Her Attorney Advisors, Four Commission Staff Members, and Representatives of the Pharmaceutical Research and Manufacturers of America). (31.32 KB)
  5. application/pdf icon Summary of Communications Placed on the Public Record Pursuant to Commission Rule 1.26(b)(5), 16 C.F.R. 1.26(b)(5) (2013) (February 26, 2013 Meeting Attended by Commissioner Ohlhausen, Two of Her Attorney Advisors, and Representatives of the Pharmaceutical Research and Manufacturers of America). (21.5 KB)